Lenalidomide (CAS 191732-72-6) Suppliers and Product Information

Lenalidomide is an immunomodulatory drug with multiple mechanisms of action, including anti-tumor, anti-angiogenic, and immunomodulatory effects. It is used in the treatment of multiple myeloma, myelodysplastic syndromes, and other hematological malignancies. Lenalidomide works by inhibiting TNF-α production, stimulating T cells, reducing serum levels of VEGF and bFGF, and promoting G1 cell cycle arrest and apoptosis of malignant cells.

Frequently Asked Questions about Lenalidomide

Q: What is the main use of Lenalidomide?

A: Lenalidomide is primarily used to treat multiple myeloma and myelodysplastic syndromes (MDS). It is also being investigated for use in other hematological malignancies and solid tumors.

Q: How does Lenalidomide work?

A: Lenalidomide works through multiple mechanisms, including inhibition of TNF-α production, stimulation of T cells, reduction of angiogenic factors, and promotion of cancer cell apoptosis. It also modulates the substrate specificity of the CRL4CRBN E3 ubiquitin ligase, leading to the degradation of specific transcription factors in multiple myeloma cells.

Q: What are the potential side effects of Lenalidomide?

A: Common side effects may include fatigue, diarrhea, nausea, rash, and cytopenias. More serious risks include an increased risk of second primary malignancies, thromboembolism, and potential teratogenicity. Close monitoring and appropriate risk management strategies are essential during treatment.

Q: How is Lenalidomide different from Thalidomide?

A: Lenalidomide is a derivative of thalidomide with structural modifications that enhance its efficacy and reduce some of the adverse effects associated with thalidomide. Lenalidomide is reported to be 100 times more potent than thalidomide in treating multiple myeloma, and its teratogenic toxicity has not been found to be as severe.